Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04811001 | Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations(CAPLAND) | unknown | Phase 2 | 170 | Fondazione Ricerca TraslazionaleOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05111197 | Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy(TRAILOCLORI01) | unknown | Phase 3 | 112 | Institut Cancerologie de l'OuestOTHER |
| 1 |
| Feb 21, 2023 |
| clinicaltrials |
| NCT05736991 | Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma | unknown | — | 600 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05737589 | Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Metastasis | unknown | — | 50 | Xiaorong DongOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03085069 | A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC | unknown | Phase 2 | 146 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04153097 | Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC | unknown | — | 500 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05445310 | Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer | unknown | Phase 2 | 114 | Peking Union Medical College HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04996927 | 18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC | unknown | — | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05257512 | Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 150 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05430386 | Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC | unknown | Phase 1 | 174 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05718167 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | unknown | Phase 3 | 570 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05533086 | PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer | unknown | — | 20 | Xiaohua ZhuOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05715398 | BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 90 | Shanghai Gopherwood Biotech Co., Ltd.INDUSTRY | 0 | Feb 10, 2023 | clinicaltrials |
| NCT05425134 | Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer | unknown | — | 5,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05716672 | Impact of Lazertinib Dose Modification on Effectiveness and Safety | unknown | — | 200 | Pusan National University HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02981108 | A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | unknown | Phase 1 / Phase 2 | 364 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03849768 | A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | unknown | Phase 3 | 429 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05675033 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2023 | clinicaltrials |
| NCT04895930 | Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC(FOCUS-A) | unknown | Phase 2 | 40 | Shanghai Chest HospitalOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT05662813 | Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy | unknown | Phase 2 | 55 | West China HospitalOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05661240 | Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment | unknown | Phase 2 / Phase 3 | 348 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT04436406 | PD-L1 Expression in Cancer (PECan Study).(PECan) | unknown | N/A | 30 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05651269 | Milciclib in Combination With Gemcitabine in Advanced NSCLC | unknown | Phase 2 | 28 | Tiziana Life Sciences LTDINDUSTRY | 0 | Dec 15, 2022 | clinicaltrials |
| NCT05648071 | First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial(SPBPDC) | unknown | Phase 3 | 60 | Qianfoshan HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05648370 | Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery | unknown | — | 60 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT04758481 | Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer | unknown | N/A | 20 | University Hospital OstravaOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03574402 | Phase II Umbrella Study Directed by Next Generation Sequencing(TRUMP) | unknown | Phase 2 | 400 | Guangdong Association of Clinical TrialsOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04459078 | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma | unknown | Phase 2 | 63 | Hunan Cancer HospitalOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05042375 | A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 450 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT04211090 | Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC(CAP-BRAIN) | unknown | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05611450 | Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted Therapy | unknown | N/A | 108 | Chang Gung Memorial HospitalOTHER | 0 | Nov 10, 2022 | clinicaltrials |
| NCT05605613 | PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial | unknown | Phase 2 / Phase 3 | 150 | Xuhua DuanOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT00100256 | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 60 | Andarix PharmaceuticalsINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05603013 | Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0) | unknown | Phase 2 | 45 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05588206 | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 21 | First People's Hospital of HangzhouOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05583409 | SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC | unknown | N/A | 72 | Li ZhangOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05577052 | SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases | unknown | N/A | 100 | Wuhan UniversityOTHER | 0 | Oct 13, 2022 | clinicaltrials |
| NCT05574998 | First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial(FTANLCNDG) | unknown | Phase 2 | 100 | Qianfoshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05565677 | Prognostic Value of Lung Cancer MicroAnatomy in 3D(LungCaMa3D) | unknown | — | 50 | Aristotle University Of ThessalonikiOTHER | 0 | Oct 4, 2022 | clinicaltrials |
| NCT05547737 | Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer(NSCLC) | unknown | — | 500 | Henan Cancer HospitalOTHER_GOV | 0 | Sep 21, 2022 | clinicaltrials |
| NCT05548348 | First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation | unknown | Phase 2 | 30 | Chongqing University Cancer HospitalOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04942275 | Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy(PEGASUS) | unknown | Phase 2 / Phase 3 | 60 | University Hospital, BrestOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT04455438 | SBRT Dose Escalation for Reirradiation of Inoperable Lung Lesions(STRILL) | unknown | N/A | 15 | Istituto Clinico HumanitasOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT04571632 | Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors(Luscid) | unknown | Phase 2 | 36 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT05534113 | Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC | unknown | Phase 2 | 38 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 14, 2022 | clinicaltrials |
| NCT05532527 | Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study(NSCLC) | unknown | N/A | 35 | Henan Provincial People's HospitalOTHER | 0 | Sep 8, 2022 | clinicaltrials |
| NCT05529355 | Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 45 | Anhui Chest HospitalOTHER | 0 | Sep 7, 2022 | clinicaltrials |
| NCT05513664 | Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer | unknown | — | 80 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 21, 2023source: clinicaltrials